Vascazen is used to treat patients with Omega-3 fatty acids deficiency.
Pivotal Therapeutics president Rachelle MacSweeney said the launch of Vascazen in North America is a key milestone for the company.
"The positive response at the AHA, is very encouraging as we move forward in executing plans to mobilize our specialty sales force to penetrate the multi-billion dollar Cardiovascular market in the United States," MacSweeney added.
The company conducted an Open Label Study which demonstrated the efficacy of Vascazen in improving Omega-3 fatty acids in the subjects.